← Leaderboards
Bernard F. Godley
University Of Texas Medical Br Galveston
$1,365,145
Attributed
$1,365,145
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,365,145 · 1
By mechanism
R01$1,365,145 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Irina A Pikuleva$16,517,384
- Yogesh Chandra Awasthi$6,761,569
- Sankar Mitra$15,620,345
- Istvan Steven Boldogh$9,318,184
- Bennett Van Houten$12,122,476
Others in their field
Top investigators on “Age Difference”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$187,267,729
- David R. Weir · University Of Michigan At Ann Arbor$156,572,971
- Lloyd D Johnston · University Of Michigan At Ann Arbor$106,109,937
- Daniel C Ralph · Cornell University$89,901,072
- Roger T Howe · University Of California-Berkeley$89,901,072
- James E. Gern · University Of Wisconsin-Madison$83,174,637
Research focus
Age DifferenceAgingCatalaseCell AgeCell DeathCellular ImmunityDna DamageElectrochemistryEnzyme ActivityFree Radical OxygenGlutathione TransferaseHigh Performance Liquid ChromatographyHuman TissueMacular DegenerationMitochondrial DnaMolecular PathologyNorthern BlottingsOrgan CultureOxidative StressPolymerase Chain ReactionRetinal Pigment EpitheliumStatistics /BiometrySuperoxide DismutaseTissue /Cell Culture
Grant awards (6)
REACTIVE OXYGEN-INDUCED DNA DAMAGE IN RETINAL CELLS$272,639
R01 · FY2004 · EY
REACTIVE OXYGEN-INDUCED DNA DAMAGE IN RETINAL CELLS$268,045
R01 · FY2003 · EY
REACTIVE OXYGEN-INDUCED DNA DAMAGE IN RETINAL CELLS$263,585
R01 · FY2002 · EY
REACTIVE OXYGEN-INDUCED DNA DAMAGE IN RETINAL CELLS$230,366
R01 · FY2001 · EY
REACTIVE OXYGEN-INDUCED DNA DAMAGE IN RETINAL CELLS$45,557
R01 · FY2001 · EY
REACTIVE OXYGEN-INDUCED DNA DAMAGE IN RETINAL CELLS$284,953
R01 · FY2000 · EY